23.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$24.00
Aprire:
$23.16
Volume 24 ore:
3.44M
Relative Volume:
0.94
Capitalizzazione di mercato:
$3.94B
Reddito:
$56.99M
Utile/perdita netta:
$-107.23M
Rapporto P/E:
-28.50
EPS:
-0.8199
Flusso di cassa netto:
$-142.55M
1 W Prestazione:
+2.68%
1M Prestazione:
-15.54%
6M Prestazione:
+41.64%
1 anno Prestazione:
+267.45%
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
TNGX
Tango Therapeutics Inc
|
23.37 | 4.05B | 56.99M | -107.23M | -142.55M | -0.8199 |
|
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-02 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-23 | Iniziato | Mizuho | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com India
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’ - Stocktwits
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance
Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics appoints Robert Azelby to Board of Directors - scanx.trade
HC Wainwright Issues Pessimistic Outlook for TNGX Earnings - MarketBeat
Research Analysts Issue Forecasts for TNGX Q2 Earnings - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada
H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com
Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Early trial shows strong pancreatic cancer resp... - Pluang
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - Stock Titan
Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Insiders Selling US$727k In Stock Relieved As Market Cap Slides To US$4.4b - Moomoo
Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX): What Does the Latest Update Mean for Clinical Progress? - Kalkine Media
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - theglobeandmail.com
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Expands At-The-Market Equity Program - The Globe and Mail
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing - Stock Titan
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses - The Globe and Mail
Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39 - Moomoo
Guggenheim raises Tango Therapeutics stock price target to $35 By Investing.com - Investing.com South Africa
Guggenheim raises Tango Therapeutics stock price target to $35 - Investing.com Nigeria
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $44.58, Implies 61% Upside - TradingView
Tango TherapeuticsFiles Prospectus To Sell Up To $400 Million In Common Stock - TradingView
Tango Therapeutics (TNGX) ups at-the-market stock capacity to $400M with new supplement - Stock Titan
Why is Tango Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):